Results from the ORATORIO trial, exploring Ocrevus (ocrelizumab), for the treatment of primary progressive forms of MS, have shown the drug stopped disease progression for more than two years in more patients than a placebo.
The findings, a highlight at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2016 Congress in London, raised hope that a treatment for patients with progressive MS may soon be available.
Xavier Montalban, a professor from the Vall d’Hebron University Hospital in Spain presented the study Evaluation Of No Evidence Of Progression Using Composite Disability Outcome Measures, In Patients With Primary Progressive Multiple Sclerosis In The ORATORIO Trial.
Ocrevus (produced by Roche) is an antibody targeting B-cells that express the CD20 molecule on its surface — a cell type researchers believe contributes significantly to neuronal damage.
In the trial, patients were evaluated every 12 weeks. The treatment was continued for 120 weeks, or until patients experienced a predetermined number of disability progression events.
Researchers measured disability with the Expanded Disability Status Scale (EDSS), but patients are also tested with the 25-foot walk test and the nine-hole peg test.
The results showed that significantly more patients receiving Ocrevus had no evidence of progression at 120 weeks in comparison to placebo — 42.7 per cent and 29.1 per cent, respectively. A larger proportion of the treated patients with no disease activity also did better on the additional tests.
Ocrevus has also been analysed in Phase 3 clinical trials for relapsing forms of MS. Those positive results were also recently announced by Roche ECTRIMS 2016.
The U.S. Food and Drug Administration and the European Medicines Agency have both accepted marketing applications for Ocrevus.
Source: Multiple Scerosis News Today © Copyright 2014 - 2016 BioNews Services, LLC (26/09/16)